Regardless of whether it's toys, cars, or high-tech gadgets, many U.S. companies have outsourced what they manufacture to ...

If approved in SM, it will compete with established targeted therapies Novartis’ Rydapt (midostaurin ... It is chasing after Vertex Pharma’s VX-548, which also targets NaV1.8 and last month ...

Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures, Novartis Venture Fund ... Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital, amongst ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...